Shopping Cart
Remove All
Your shopping cart is currently empty
Fosfenopril (Fosinoprilat) is a potent angiotensin-converting enzyme (ACE) inhibitor that mitigates lipopolysaccharide-induced inflammation in monocytes through the suppression of TLR4/NF-κB signaling pathways, and Fosfenopril is utilized in cardiovascular and anti-inflammatory research to investigate molecular mechanisms of ACE inhibition.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $138 | - | In Stock |
| Description | Fosfenopril (Fosinoprilat) is a potent angiotensin-converting enzyme (ACE) inhibitor that mitigates lipopolysaccharide-induced inflammation in monocytes through the suppression of TLR4/NF-κB signaling pathways, and Fosfenopril is utilized in cardiovascular and anti-inflammatory research to investigate molecular mechanisms of ACE inhibition. |
| In vitro | Fosfenopril (0-10 μM) treatment for 5 minutes can inhibit the LPS-induced increase in TLR4 expression [1]. Fosfenopril (0-10 μM) treatment for 1 hour can reduce the LPS-activated NF-κB expression level [1]. Fosfenopril also inhibits the expression of LPS-induced pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) [1]. |
| In vivo | Single intravenous injection of Fosfenopril (0.5 mg/kg bolus plus 0.1 mg/kg/min) can increase para-aminohippuric acid (PAH) clearance and glomerular filtration rate (GFR) in canines [3]. |
| Synonyms | SQ27519, SQ 27519, Fosinoprilic acid, Fosinoprilat |
| Molecular Weight | 435.49 |
| Formula | C23H34NO5P |
| Cas No. | 95399-71-6 |
| Smiles | C(CP(CCCCC1=CC=CC=C1)(=O)O)(=O)N2C[C@@H](C[C@H]2C(O)=O)C3CCCCC3 |
| Relative Density. | 1.238g/cm3 |
| Color | White |
| Appearance | Lyophilized powder |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (183.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.58 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.